FY2026 EPS Estimates for Wave Life Sciences Cut by B. Riley

Wave Life Sciences Ltd. (NASDAQ:WVE) – Analysts at B. Riley dropped their FY2026 earnings estimates for Wave Life Sciences in a report issued on Thursday, April 10th. B. Riley analyst M. El-Saadi now expects that the company will post earnings of ($1.15) per share for the year, down from their previous forecast of ($0.96). The consensus estimate for Wave Life Sciences’ current full-year earnings is ($1.14) per share. B. Riley also issued estimates for Wave Life Sciences’ FY2027 earnings at ($0.25) EPS, FY2028 earnings at $0.14 EPS and FY2029 earnings at $0.84 EPS.

Other equities research analysts have also recently issued reports about the stock. StockNews.com upgraded shares of Wave Life Sciences from a “sell” rating to a “hold” rating in a report on Saturday, March 8th. Jefferies Financial Group began coverage on Wave Life Sciences in a research note on Tuesday, February 25th. They issued a “buy” rating and a $26.00 target price for the company. HC Wainwright reaffirmed a “buy” rating and set a $22.00 price target on shares of Wave Life Sciences in a research note on Wednesday, March 26th. Finally, Wedbush started coverage on Wave Life Sciences in a research note on Tuesday, April 8th. They issued an “outperform” rating and a $18.00 price objective for the company. Two equities research analysts have rated the stock with a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $22.18.

Wave Life Sciences Stock Up 6.2 %

Shares of WVE stock opened at $6.00 on Monday. The firm has a 50 day moving average of $9.32 and a 200-day moving average of $11.66. The company has a market cap of $920.92 million, a price-to-earnings ratio of -5.41 and a beta of -0.93. Wave Life Sciences has a 52 week low of $4.25 and a 52 week high of $16.74.

Wave Life Sciences (NASDAQ:WVE) last released its earnings results on Tuesday, March 4th. The company reported $0.17 EPS for the quarter, topping the consensus estimate of ($0.17) by $0.34. Wave Life Sciences had a negative return on equity of 280.57% and a negative net margin of 66.50%. The business had revenue of $83.75 million during the quarter, compared to analysts’ expectations of $25.60 million.

Institutional Investors Weigh In On Wave Life Sciences

A number of hedge funds have recently made changes to their positions in WVE. GF Fund Management CO. LTD. purchased a new stake in Wave Life Sciences during the fourth quarter worth about $40,000. Quarry LP bought a new position in shares of Wave Life Sciences during the 4th quarter valued at approximately $62,000. KBC Group NV bought a new position in shares of Wave Life Sciences during the 4th quarter valued at approximately $67,000. Summit Investment Advisors Inc. increased its stake in shares of Wave Life Sciences by 31.5% during the 4th quarter. Summit Investment Advisors Inc. now owns 9,642 shares of the company’s stock worth $119,000 after purchasing an additional 2,308 shares during the last quarter. Finally, Westwood Wealth Management bought a new stake in shares of Wave Life Sciences in the 4th quarter worth approximately $124,000. 89.73% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other news, Director Christian O. Henry sold 10,500 shares of the business’s stock in a transaction that occurred on Thursday, March 20th. The stock was sold at an average price of $9.77, for a total value of $102,585.00. Following the transaction, the director now owns 16,115 shares in the company, valued at $157,443.55. The trade was a 39.45 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Paul Bolno sold 169,025 shares of the stock in a transaction that occurred on Friday, March 7th. The shares were sold at an average price of $9.57, for a total value of $1,617,569.25. Following the sale, the chief executive officer now directly owns 338,351 shares of the company’s stock, valued at $3,238,019.07. The trade was a 33.31 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 29.10% of the company’s stock.

Wave Life Sciences Company Profile

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders.